AlloVir, Inc. (NASDAQ:ALVR – Get Free Report)’s stock price traded up 1.8% during mid-day trading on Thursday . The company traded as high as $3.46 and last traded at $3.40. Approximately 100,018 shares changed hands during trading, an increase of 538% from the average session volume of 15,685 shares. The stock had previously closed at $3.34.
AlloVir Trading Up 1.8%
The company has a market cap of $17.15 million, a P/E ratio of -0.17 and a beta of 0.63. The business’s 50 day simple moving average is $4.47 and its 200 day simple moving average is $6.58.
About AlloVir
AlloVir, Inc is a clinical-stage biopharmaceutical company specializing in the development of off-the-shelf, allogeneic virus-specific T-cell immunotherapies for the prevention and treatment of life-threatening viral infections in immunocompromised patients. The company’s proprietary Multi-Virus-Targeting Cell (MTC) platform enables the rapid identification, isolation and expansion of virus-specific T cells from healthy donors, with the aim of offering broad coverage against multiple clinically significant viruses.
AlloVir’s pipeline includes several product candidates designed to address unmet needs in transplant medicine and other immunosuppressed settings.
See Also
- Five stocks we like better than AlloVir
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.
